Biotech

All Articles

BMS axes bispecific months after submitting to operate period 3 test

.Bristol Myers Squibb has actually had a whiplash change of mind on its BCMA bispecific T-cell engag...

Charles Baum manages Terremoto as CEO

.Charles Baum, M.D., Ph.D., that managed Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Sq...

Asarina to shut after initiatives to partner Tourette's drug neglect

.After communicating to much more than 200 firms to partner a Tourette syndrome treatment that showe...

Novartis pens $150M beforehand bispecifics deal with Dren Bio

.Novartis has possessed some rotten luck with bispecific antitoxins in the past, but evaluating by t...

AstraZeneca plants an EGFR plant with Pinetree deal worth $45M

.Pinetree Rehabs are going to help AstraZeneca plant some trees in its pipeline along with a brand n...

GRO gathers $60M collection B to take gout arthritis therapy into clinic

.GRO Biosciences has ended the full week along with an additional $60.3 million in the banking compa...

Chutes &amp Ladders-- Gilead's Merdad Parsey goes, Cassava loses chief executive officer

.Welcome to this week's Chutes &amp Ladders, our roundup of notable leadership hirings, firings and ...